Point72 DIFC Ltd bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,842 shares of the company’s stock, valued at approximately $118,000.
Several other hedge funds have also bought and sold shares of CATX. Janus Henderson Group PLC purchased a new stake in shares of Perspective Therapeutics in the 1st quarter valued at $15,511,000. Affinity Asset Advisors LLC purchased a new position in shares of Perspective Therapeutics in the first quarter worth about $6,069,000. Vanguard Group Inc. increased its holdings in shares of Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after buying an additional 4,566,356 shares during the period. Ally Bridge Group NY LLC purchased a new stake in Perspective Therapeutics during the 2nd quarter valued at about $3,951,000. Finally, WealthPLAN Partners LLC bought a new position in Perspective Therapeutics during the 2nd quarter worth approximately $1,695,000. 54.66% of the stock is currently owned by institutional investors.
Perspective Therapeutics Stock Performance
NYSE CATX opened at $12.59 on Wednesday. Perspective Therapeutics, Inc. has a 12 month low of $2.20 and a 12 month high of $19.05. The business has a 50 day simple moving average of $13.81.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on CATX shares. Wedbush started coverage on Perspective Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $25.00 target price for the company. Bank of America initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 target price for the company. Oppenheimer reduced their price objective on Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Truist Financial assumed coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $20.71.
Get Our Latest Analysis on Perspective Therapeutics
Perspective Therapeutics Profile
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Further Reading
- Five stocks we like better than Perspective Therapeutics
- Consumer Staples Stocks, Explained
- Ready for Growth? Barrick Gold Stock Could Be the Answer
- The Basics of Support and Resistance
- Trade Like a Member of Congress With These 2 ETFs
- What to Know About Investing in Penny Stocks
- October’s Top 3 Stocks Revealed by MarketBeat’s MarketRank Tool
Want to see what other hedge funds are holding CATX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perspective Therapeutics, Inc. (NYSE:CATX – Free Report).
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.